Research Publications

Back

Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax


Hupalo, DN; Luo, Z; Melnikov, A; Sutton, PL; Rogov, P; Escalante, A; Vallejo, AF; Herrera, S; Arevalo-Herrera, M; Fan, Q; Wang, Y; Cui, L; LUCAS, CM; Durand, S; Sanchez, JF; Baldeviano, GC; Lescano, AG; Laman, M; Barnadas, C; Barry, A; Mueller, I; Kazura, JW; Eapen, A; Kanagaraj, D; Valecha, N; Ferreira, MU; Roobsoong, W; Nguitragool, W; Sattabonkot, J; Gamboa, D; Kosek, M; Vinetz, JM; Gonzalez-Ceron, L; Birren, BW; Neafsey, DE; Carlton, JM
2016-06-27
Nat Genet
Journal Article
48
8
953-8
Plasmodium vivax is a major public health burden, responsible for the majority of malaria infections outside Africa. We explored the impact of demographic history and selective pressures on the P. vivax genome by sequencing 182 clinical isolates sampled from 11 countries across the globe, using hybrid selection to overcome human DNA contamination. We confirmed previous reports of high genomic diversity in P. vivax relative to the more virulent Plasmodium falciparum species; regional populations of P. vivax exhibited greater diversity than the global P. falciparum population, indicating a large and/or stable population. Signals of natural selection suggest that P. vivax is evolving in response to antimalarial drugs and is adapting to regional differences in the human host and the mosquito vector. These findings underline the variable epidemiology of this parasite species and highlight the breadth of approaches that may be required to eliminate P. vivax globally.
NPG
Infection and Immunity; Population Health and Immunity
10.1038/ng.3588
27348298
Refer to article for additional funding acknowledgements
Refer to copyright notice on published article.

Back
Creation Date 2016-08-09 12:01:46 Last Modified 2017-09-11 11:55:31